LAB Stock Overview
Provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.15 |
| 52 Week High | US$2.94 |
| 52 Week Low | US$0.97 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | -29.45% |
| 1 Year Change | -58.78% |
| 3 Year Change | -66.67% |
| 5 Year Change | -46.01% |
| Change since IPO | -91.80% |
Recent News & Updates
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
Mar 26 Strategic mergers and partnerships, along with cost synergies, aim to improve profitability and net margins significantly.Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 01
Recent updates
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
Mar 26 Strategic mergers and partnerships, along with cost synergies, aim to improve profitability and net margins significantly.Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 01Market Cool On Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 28% Lower
Feb 21Is Standard BioTools (NASDAQ:LAB) Using Debt Sensibly?
Feb 09After Leaping 35% Standard BioTools Inc. (NASDAQ:LAB) Shares Are Not Flying Under The Radar
Dec 17Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
Oct 26Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Sep 14Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 05Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%
Jul 26Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Apr 09Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Mar 06Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Feb 17Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?
Jan 12Is Standard BioTools (NASDAQ:LAB) A Risky Investment?
Aug 13Shareholder Returns
| LAB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 7.5% | 0.9% | 5.4% |
| 1Y | -58.8% | -27.4% | 3.6% |
Return vs Industry: LAB underperformed the US Life Sciences industry which returned -31.3% over the past year.
Return vs Market: LAB underperformed the US Market which returned -0% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 13.9% |
| Life Sciences Industry Average Movement | 10.4% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: LAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LAB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 816 | Michael Egholm | www.standardbio.com |
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications.
Standard BioTools Inc. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | US$416.88m |
| Earnings (TTM) | -US$184.90m |
| Revenue (TTM) | US$174.43m |
2.5x
P/S Ratio-2.4x
P/E RatioIs LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | US$174.43m |
| Cost of Revenue | US$90.17m |
| Gross Profit | US$84.26m |
| Other Expenses | US$269.16m |
| Earnings | -US$184.90m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 48.31% |
| Net Profit Margin | -106.00% |
| Debt/Equity Ratio | 0.06% |
How did LAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 12:27 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Standard BioTools Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| Shawn Bevec | Deutsche Bank |